Crohn's disease biologics comparison
GastroenterologyCompare biologic and targeted therapies for moderate-to-severe Crohn's disease. TNF inhibitors were the first biologics for Crohn's; newer options include IL-23 inhibitors, integrin inhibitors, and JAK inhibitors.
Select any two to compare side by side
All products in this comparison
| Product | Manufacturer | Route | Frequency | Key difference |
|---|---|---|---|---|
| Remicade | Janssen | IV infusion | Every 8 weeks (after loading) | First biologic for Crohn's; biosimilars preferred by payers; proven fistula data |
| Humira | AbbVie | SC injection | Every 2 weeks | SC TNF inhibitor; biosimilars available; most prescribed |
| Stelara | Janssen | IV induction → SC maintenance | Every 8 weeks (after IV induction) | IL-12/23 inhibitor; IV induction, SC maintenance; biosimilars available |
| Entyvio | Takeda | IV infusion or SC injection | Every 8 weeks (IV) or every 2 weeks (SC) | Gut-selective integrin inhibitor; favorable safety profile; SC option |
| Skyrizi | AbbVie | IV induction → SC maintenance | Every 8 weeks (after IV induction) | IL-23 inhibitor; high endoscopic response rates; newer for Crohn's |
| Cimzia | UCB | SC injection | Every 4 weeks (after loading) | PEGylated TNFi; preferred in pregnancy (no active placental transfer) |
| Tysabri | Biogen | IV infusion | Every 4 weeks | Integrin inhibitor; high efficacy; PML risk requires JCV monitoring |
| Rinvoq | AbbVie | Oral (tablet) | Daily | Oral JAK inhibitor; black-box warning limits positioning |
Related guides
Denied one of these medications?
Ellen can decode your denial letter, identify why you were denied, and generate a personalized appeal, free for patients.